the minutes noted that the future role of mr ralph and the colorado contract were "for urgent consideration" but that these issues "may be totally or partially resolved with the termination of paul ralph".
if the transaction embodied in the share sale agreement satisfied the pre-conditions in paragraph 1 of the bonus provision then that transaction was completed on the fifth business day after the shareholder's approval (7 august 2007).
in this case, the evidence to which i have referred displaces any inference that the market value of the scrip paid by medivac for the sale of diakyne was 4 cents a share.